NasdaqGM:RAPPPharmaceuticals
Can RAP-219’s Extended Half-Life Redefine Rapport Therapeutics’ (RAPP) Long-Term Epilepsy Strategy?
Rapport Therapeutics recently reported Phase 2a follow-up data for its investigational epilepsy drug RAP-219 in drug-resistant focal onset seizures, showing sustained reductions in both long episodes and clinical seizures over a 16-week period with generally favorable tolerability.
An intriguing aspect of the update is RAP-219’s longer-than-previously-estimated 22-day half-life, which appears to maintain therapeutic receptor occupancy and seizure control well beyond the initial 8-week dosing...